Business
WellBiome® clinical trial on surgical outcomes
OptiBiotix Health plc has initiated a clinical study with Hull University Teaching Hospital NHS Trust to assess the impact of its WellBiome prebiotic on cardiac surgery outcomes and potential NHS cost savings. This double-blind, placebo-controlled study will involve up to 60 patients and evaluate the effects of six-week pre-operative supplementation on intensive care time, hospital stay duration, and post-operative complications, with a cost savings analysis also included. The company highlights WellBiome's patented mineral-enriched prebiotic fibre complex, designed to enhance gut microbiome diversity and offering various health benefits, as a response to growing consumer interest in gut health. Disclaimer*
About this update from Optibiotix Health Plc
OptiBiotix Health plc ("OptiBiotix" or the "Company" or the "Group") Clinical trial to evaluate the effect of WellBiome® on surgical outcomes and NHS cost savings OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes. This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotics like WellBiome in improving health outcomes and cost savings. WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: - · Nourishes beneficial bacteria throughout the entire gut to improve gut health · Contributes to improved bone health by aiding the absorption of essential minerals · Contributes to normal muscle function, including heart muscle · Supports normal brain health function and memory · Contributes to normal psychological function · &...
View stock analysis, news, and events for Optibiotix Health Plc